HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on ...

The abstract entitled “A rapid and scalable thymus organoid development method for generating functional T cells” presents progress on the development of a transplantable and scalable artificial ...

The abstract entitled "A rapid and scalable thymus organoid development method for generating functional T cells” presents progress on the development of a transplantable and scalable artificial ...

The abstract entitled “A rapid and scalable thymus organoid development method for generating functional T cells” presents progress on the development of a transplantable and scalable ...

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment.

Researchers have shown that gonadotrophs, cells in the pituitary gland with a key role in puberty and reproduction, come from two different populations, with the majority produced after birth rather ...

HCW9206 is designed to improve the production process of chimeric antigen receptor T-cells (CAR-Ts), a transformative approach in treating various cancers. The protein has shown to be superior to ...

AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer Research Ⓡ (AACR) 116th Annual Meeting at ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for ...

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy London, 19 May 2025- LIfT BioSciences, ('LIfT' or 'the ...

Acrivon Therapeutics presents data on ACR-2316's tumor cell death mechanisms and early clinical trial results at AACR 2025. Acrivon Therapeutics has announced that it will present findings on ACR ...